May 12, 2020
Mylan to Supply Investigational Antiviral Remdesivir for the Potential Treatment of COVID-19
May 11, 2020
Mylan Reports First Quarter 2020 Results and Reaffirms 2020 Guidance
May 08, 2020
Mylan to Present at the BofA Securities Virtual Health Care Conference 2020
May 04, 2020
Mylan Releases "A Legacy of Impact: 2019 Global Social Responsibility Report"
Apr 15, 2020
Mylan Board Appoints Robert J. Coury As Executive Chairman of Mylan N.V.
Apr 08, 2020
Mylan Updates Its Efforts Regarding COVID-19
Mar 27, 2020
Mylan and Lupin Announce Positive CHMP Opinion for Nepexto®, Biosimilar Etanercept
Mar 26, 2020
Mylan and Pfizer Provide Update Regarding Proposed Combination of Mylan and Upjohn
Mar 25, 2020
Mylan Announces Additional Efforts to Support Response to the COVID-19 Pandemic by Voluntarily Waiving its Marketing Exclusivity in the U.S. for Lopinavir/Ritonavir to Help Ensure Wider Availability to Meet Potential COVID-19 Patient Needs
Mar 09, 2020
U.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocon's Proposed Biosimilar Bevacizumab for Review
Feb 27, 2020
Mylan and Pfizer Announce Appointment of Viatris Chief Financial Officer
Feb 27, 2020
Mylan and Pfizer Finalize Appointments to Viatris Board of Directors
Feb 18, 2020
Mylan to Release 2019 Fourth Quarter, Full Year Results and 2020 Guidance on Feb. 27, 2020
Jan 06, 2020
Mylan to Present at the 38th Annual J.P. Morgan Healthcare Conference
Dec 02, 2019
Mylan and Biocon Launch Trastuzumab Biosimilar, Ogivri(TM) (trastuzumab-dkst), in the U.S.
Nov 25, 2019
Mylan to Present at the Evercore ISI HealthCONx Conference
Nov 12, 2019
Mylan and Pfizer Announce Viatris as the New Company Name in the Planned Mylan-Upjohn Combination
Nov 05, 2019
Mylan Reports Third Quarter 2019 Results and Updates 2019 Guidance
Oct 25, 2019
Mylan Pharmaceuticals Initiates Voluntary Nationwide Recall of One Lot of Alprazolam Tablets, USP C-IV 0.5 mg, Due to the Potential of Foreign Substance
Oct 24, 2019
Mylan to Release Third Quarter 2019 Financial Results on Nov. 5, 2019